Related references
Note: Only part of the references are listed.Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Targeting regulatory T cells in anti-PD-1/PD-L1 cancer immunotherapy
Galina Zhulai et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2022)
Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas
Kwong Yok Tsang et al.
CANCERS (2022)
Mechanism and strategies of immunotherapy resistance in colorectal cancer
Jiqi Shan et al.
FRONTIERS IN IMMUNOLOGY (2022)
Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201
Kwong Y. Tsang et al.
CANCERS (2022)
AN ANTI-CARCINOMA MONOCLONAL ANTIBODY (MAB) NEO-201 CAN ALSO TARGET HUMAN ACUTE MYELOID LEUKEMIA (AML) CELL LINES IN VITRO
Alessandra Romano et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy
Cristina Zalfa et al.
FRONTIERS IN IMMUNOLOGY (2021)
The augment of regulatory T cells undermines the efficacy of anti-PD-L1 treatment in cervical cancer
Fengying Xu et al.
BMC IMMUNOLOGY (2021)
Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
Beatriz Honrubia-Peris et al.
CANCERS (2021)
Evaluation of the Anti-Tumor Activity of the Humanized Monoclonal Antibody NEO-201 in Preclinical Models of Ovarian Cancer
Kristen P. Zeligs et al.
FRONTIERS IN ONCOLOGY (2020)
Maintenance avelumab for metastatic urothelial cancer: a new standard of care
Alisa Erck et al.
CANCER BIOLOGY & THERAPY (2020)
NKG2D and MICA/B shedding: a 'tag game' between NK cells and malignant cells
Samantha Xing et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2020)
Tumor-Derived Soluble MICA Obstructs the NKG2D Pathway to Restrain NK Cytotoxicity
Qizhi Luo et al.
AGING AND DISEASE (2020)
Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
James B. Wing et al.
IMMUNITY (2019)
The TNF Paradox in Cancer Progression and Immunotherapy
Anne Montfort et al.
FRONTIERS IN IMMUNOLOGY (2019)
Truncated O-glycans promote epithelial-to-mesenchymal transition and stemness properties of pancreatic cancer cells
Divya Thomas et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB
Ingrid Teige et al.
FRONTIERS IN IMMUNOLOGY (2019)
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas
Massimo Fantini et al.
FRONTIERS IN IMMUNOLOGY (2018)
Multiple Roles of Glycans in Hematological Malignancies
Xingchen Pang et al.
FRONTIERS IN ONCOLOGY (2018)
Cancer-FOXP3 directly activated CCL5 to recruit FOXP3+ Treg cells in pancreatic ductal adenocarcinoma
X. Wang et al.
ONCOGENE (2017)
Soluble MICA is elevated in pancreatic cancer: Results from a population based case-control study
Guillaume Onyeaghala et al.
MOLECULAR CARCINOGENESIS (2017)
Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
Jie Bai et al.
ONCOTARGET (2017)
Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor
Tomasz Maj et al.
NATURE IMMUNOLOGY (2017)
Pharmacokinetics of Monoclonal Antibodies
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Short O-GalNAc glycans: regulation and role in tumor development and clinical perspectives
Joanne Chia et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2016)
Cancer immunotherapy: harnessing the immune system to battle cancer
Yiping Yang
JOURNAL OF CLINICAL INVESTIGATION (2015)
Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3high regulatory T cells in humans
Makoto Miyara et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Glycosylation in cancer: mechanisms and clinical implications
Salome S. Pinho et al.
NATURE REVIEWS CANCER (2015)
IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity
Martin Oft
CANCER IMMUNOLOGY RESEARCH (2014)
Soluble Carcinoembryonic Antigen Activates Endothelial Cells and Tumor Angiogenesis
Kira H. Bramswig et al.
CANCER RESEARCH (2013)
Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies
Ursula J. E. Seidel et al.
FRONTIERS IN IMMUNOLOGY (2013)
Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression
Vanja Sisirak et al.
CANCER RESEARCH (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Complement and cellular cytotoxicity in antibody therapy of cancer
Siao-Yi Wang et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Soluble MICA in malignant diseases
S Holdenrieder et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma:: Evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions
B Davidson et al.
HUMAN PATHOLOGY (2000)
Share Paper
